Journal article

GRIN2B encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects

K Platzer, H Yuan, H Schütz, A Winschel, W Chen, C Hu, H Kusumoto, HO Heyne, KL Helbig, S Tang, MC Willing, BT Tinkle, DJ Adams, C Depienne, B Keren, C Mignot, E Frengen, P Strømme, S Biskup, D Döcker Show all

Journal of Medical Genetics | BMJ PUBLISHING GROUP | Published : 2017

Abstract

Background: We aimed for a comprehensive delineation of genetic, functional and phenotypic aspects of GRIN2B encephalopathy and explored potential prospects of personalised medicine. Methods: Data of 48 individuals with de novo GRIN2B variants were collected from several diagnostic and research cohorts, as well as from 43 patients from the literature. Functional consequences and response to memantine treatment were investigated in vitro and eventually translated into patient care. Results: Overall, de novo variants in 86 patients were classified as pathogenic/likely pathogenic. Patients presented with neurodevelopmental disorders and a spectrum of hypotonia, movement disorder, cortical visua..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institutes of Health


Funding Acknowledgements

Funding for the project was provided by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (R01HD082373 to HY), by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454 (to HY), and by the National Institute of Neurological Disorders and Stroke (NS036654, R01NS065371 and R24NS092989 to SFT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Additional funding was received from the Australian NHMRC (512123 to TR), NIH NINDS training grant (K12 NS049453 to EMG), Cure Kids NZ to LS and the SNSF Early Postdoc fellowship (P2SKP3_164945 to CC). Funding for the DECIPHER project was provided by the Wellcome Trust.